J Diabetes Invest2014; 5: 501--506

Introduction {#jdi12170-sec-0005}
============

Epidemiological studies have shown that low levels of high‐density lipoprotein (HDL) cholesterol (HDLC) are associated with cardiovascular disease risk[1](#jdi12170-bib-0001 jdi12170-bib-0002){ref-type="ref"}. A recent report showed that HDL protects against cardiovascular disease in both males and females, independent of age, smoking status, systolic blood pressure and total cholesterol[3](#jdi12170-bib-0003){ref-type="ref"}. In addition, considering the global epidemics of type 2 diabetes and metabolic syndrome, the impact of low HDLC level as a risk factor for cardiovascular disease is likely to increase rapidly in the future[4](#jdi12170-bib-0004 jdi12170-bib-0005){ref-type="ref"}.

HDL exerts anti‐atherogenic actions through its intrinsic anti‐oxidative and anti‐inflammatory properties[6](#jdi12170-bib-0006){ref-type="ref"}. In addition, increased reactive oxygen species levels are thought to be an important trigger of insulin resistance[7](#jdi12170-bib-0007){ref-type="ref"}, a common feature of type 2 diabetes. Accordingly, low HDL level might be associated with impaired glucose tolerance (IGT) and development of type 2 diabetes.

Japanese--Americans who share a virtually identical genetic makeup with native Japanese currently living in Japan have lived Westernized lifestyles for decades[8](#jdi12170-bib-0008 jdi12170-bib-0009){ref-type="ref"}. We have reported that the prevalence of metabolic syndrome among Japanese--Americans is significantly higher, and serum HDLC levels are significantly lower, than among native Japanese[10](#jdi12170-bib-0010){ref-type="ref"}. In addition, we have reported that the prevalences of type 2 diabetes and cardiovascular disease among Japanese--Americans are significantly higher than among native Japanese[8](#jdi12170-bib-0008){ref-type="ref"}. The purpose of the present study was to investigate the impact of serum HDLC level on the development of type 2 diabetes, and to investigate whether its effect was modified by Westernized lifestyle based on a comparison between Japanese--Americans living in Hawaii and Los Angeles, and Japanese living in Japan.

Materials and Methods {#jdi12170-sec-0006}
=====================

Study Participants and Methods {#jdi12170-sec-0007}
------------------------------

The Hawaii--Los Angeles--Hiroshima study, initiated in 1970, is part of a long‐term epidemiological study of risk factors for diabetes and cardiovascular disease in which subjects living in Hawaii and Los Angeles, California, were limited to a population genetically identical to the Japanese population. This epidemiological study was previously described in detail elsewhere[10](#jdi12170-bib-0010 jdi12170-bib-0011 jdi12170-bib-0012 jdi12170-bib-0013){ref-type="ref"}. The Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center provides health management services to approximately 110,000 atomic bomb survivors living primarily in Hiroshima, Japan[14](#jdi12170-bib-0014){ref-type="ref"}.

Study participants were Japanese--Americans consisting of 487 men and 646 women who were enrolled in medical surveys carried out from 1988 to 2010, and native Japanese consisting of 438 men and 634 women, matched on age and sex to the Japanese--Americans, who were enrolled in medical surveys carried out from 1963 to 2012. Participants were free from diabetes at start of follow up, as ascertained by the 75‐g oral glucose tolerance test (OGTT), and were examined at least twice during the study periods.

Participants underwent physical examinations and provided blood samples after an overnight fast. The Japanese--American participants underwent the OGTT during each follow‐up examination. The Japanese participants underwent the OGTT a few days later if their plasma glucose was ≥5.55 mmol/L at fasting, ≥7.21 mmol/L within 1.5 h after eating, ≥6.66 mmol/L between 1.5 and 2.5 h after eating, or ≥6.10 mmol/L beyond 2.5 h after eating, and if they showed glycosuria in the course of a screening health examination at the Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center[14](#jdi12170-bib-0014){ref-type="ref"}. All incident diabetes cases were diagnosed on the basis of the OGTT according to the 1997 American Diabetes Association criteria (fasting glucose ≥7.0 mmol/L or 2‐h glucose ≥11.1 mmol/L after an OGTT)[15](#jdi12170-bib-0015){ref-type="ref"}.

Participants were free of infectious symptoms, autoimmune diseases and other acute conditions, as assessed by medical interview. Written informed consent was obtained. The study was approved by the ethics committees of Hiroshima University, the Council of Hiroshima Kenjin‐Kai Association in Hawaii and Los Angeles, and the Hiroshima Atomic Bomb Casualty Council, Health Management and Promotion Center.

Statistical Analysis {#jdi12170-sec-0008}
--------------------

Data are described as mean ± standard deviation. Because the triglyceride and body mass index (BMI) variables did not conform to normal distributions, they were analyzed after logarithmic transformation. Continuous variables were compared by analysis of covariance. Differences in frequency between the Japanese--Americans and native Japanese were tested by the χ^2^‐test. To test the significance of HDLC level as a predictor of incidence of type 2 diabetes, HDLC concentration was divided into quartiles based on population values (\<1.11, 1.11--1.37, 1.38--1.60 and \>1.60 mmol/L in Japanese--Americans; and \<1.34, 1.34--1.60, 1.61--1.89, and \>1.89 mmol/L in native Japanese); quartile‐specific hazard ratios were estimated with the Cox proportional hazards model. With respect to potential confounders, adjustment was made for continuous age and BMI, as well as categorical sex and OGTT (normal glucose tolerance \[NGT\] and IGT). Hazard ratios were estimated after adjustment by two sets of potential confounders: the first set comprised age and sex only, and the second set comprised age, sex, category of OGTT, and BMI. The proportional hazards assumption was verified by inspection of log--log survival curves, and by examination of Schoenfeld partial residuals[16](#jdi12170-bib-0016){ref-type="ref"}. The SAS software package version 8.2 (SAS Institute, Cary, NC, USA) was used for analyses.

Results {#jdi12170-sec-0009}
=======

Japanese--American participants were followed for an average of 8.75 ± 5.27 years, and the mean age at the time of follow‐up initiation was 61.3 ± 10.8 years. Native Japanese participants were followed for an average of 7.00 ± 4.39 years, with the mean age at the time of follow‐up initiation being 61.9 ± 7.1 years. Baseline clinical characteristics of the participants are shown in Table [1](#jdi12170-tbl-0001){ref-type="table-wrap"}. A total of 181 and 175 participants developed diabetes during the follow‐up period among Japanese--Americans and native Japanese, respectively. The proportion of IGT participants among the native Japanese was greater than among Japanese--Americans (*P *\< 0.0001). The Japanese--Americans had significantly higher systolic blood pressure (SBP; *P *\< 0.0001), BMI (*P *= 0.013), triglycerides (*P *\< 0.0001) and non‐HDL cholesterol (*P *\< 0.0001) compared with the native Japanese. The Japanese--Americans had significantly lower fasting glucose (*P *\< 0.0001), 2‐h glucose (*P *\< 0.0001) and HDLC level (*P *\< 0.0001) compared with the native Japanese.

###### Clinical characteristics at baseline among Japanese--American and native Japanese study participants

                                    Japanese--Americans   Native Japanese   *P*
  --------------------------------- --------------------- ----------------- ----------
  *n* (Men/women)                   1133 (487/646)        1072 (438/634)    0.312
  NGT/IGT (*n*)                     894/239               654/418           \<0.0001
  Developed type 2 diabetes (*n*)   181                   175               
  Age (years)                       61.3 ± 10.8           61.9 ± 7.1        0.782
  SBP (mmHg)                        136 ± 20              131 ± 18          \<0.0001
  DBP (mmHg)                        77 ± 11               77 ± 10           0.399
  BMI (kg/m^2^)                     23.5 ± 3.6            23.0 ± 3.0        0.013
  Fasting glucose (mmol/L)          4.94 ± 0.55           5.44 ± 0.55       \<0.0001
  2‐h glucose (mmol/L)              6.22 ± 1.78           6.99 ± 1.66       \<0.0001
  Total cholesterol (mmol/L)        5.79 ± 0.96           5.74 ± 0.93       0.091
  Triglycerides (mmol/L)            1.74 ± 1.40           1.37 ± 0.86       \<0.0001
  HDL cholesterol (mmol/L)          1.39 ± 0.38           1.63 ± 0.43       \<0.0001
  Non‐HDL cholesterol (mmol/L)      4.39 ± 0.99           4.11 ± 0.95       \<0.0001

Data are expressed as mean ± standard deviation. BMI, body mass index; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; SBP, systolic blood pressure.
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Clinical characteristics of participants at baseline, divided by quartiles of HDLC after adjustment for age, sex and category of OGTT, are shown in Tables [2](#jdi12170-tbl-0002){ref-type="table-wrap"} and [3](#jdi12170-tbl-0003){ref-type="table-wrap"}. Among Japanese--Americans, the participants in the third and fourth quartiles were significantly older, and had lower 2‐h glucose compared with participants in the first quartile (*P *\< 0.05). Participants in the second, third and fourth quartiles had significantly lower BMI, lower fasting glucose, lower triglycerides, and lower non‐HDL cholesterol compared with participants in the first quartile (*P *\< 0.05). Participants in the fourth quartile had significantly higher total cholesterol compared with participants in the first quartile (*P *\< 0.05; Table [2](#jdi12170-tbl-0002){ref-type="table-wrap"}). Among the native Japanese, participants in the second and fourth quartiles had significantly lower DBP compared with participants in the first quartile (*P *\< 0.05). Participants in the third and fourth quartiles had significantly lower BMI, lower fasting glucose, lower 2‐h glucose and lower non‐HDL cholesterol compared with participants in the first quartile (*P *\< 0.05). Participants in the second, third, and fourth quartiles had significantly higher total cholesterol and lower triglycerides compared with participants in the first quartile (*P *\< 0.05; Table [3](#jdi12170-tbl-0003){ref-type="table-wrap"}).

###### Clinical characteristics at baseline among Japanese--American participants

                                    HDLC                                                                                                                        
  --------------------------------- --------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  *n* (NGT/IGT)                     306 (184/122)   293 (127/166)                                         252 (97/155)                                          282 (79/203)
  Developed type 2 diabetes (*n*)   77              45                                                    31                                                    28
  Age (years)                       59.5 ± 12.1     61.5 ± 10.2                                           62.5 ± 10.8[\*](#jdi12170-note-0002){ref-type="fn"}   62.0 ± 10.9[\*](#jdi12170-note-0002){ref-type="fn"}
  SBP (mmHg)                        137 ± 20        137 ± 20                                              135 ± 20                                              133 ± 21
  DBP (mmHg)                        79 ± 11         78 ± 11                                               76 ± 12                                               75 ± 12
  BMI (kg/m^2^)                     25.0 ± 3.0      23.7 ± 3.1[\*](#jdi12170-note-0002){ref-type="fn"}    23.2 ± 3.4[\*](#jdi12170-note-0002){ref-type="fn"}    21.9 ± 3.5[\*](#jdi12170-note-0002){ref-type="fn"}
  Fasting glucose (mmol/L)          5.05 ± 0.55     4.94 ± 0.50[\*](#jdi12170-note-0002){ref-type="fn"}   4.88 ± 0.50[\*](#jdi12170-note-0002){ref-type="fn"}   4.83 ± 0.55[\*](#jdi12170-note-0002){ref-type="fn"}
  2‐h glucose (mmol/L)              6.55 ± 1.83     6.33 ± 1.78                                           5.99 ± 1.83[\*](#jdi12170-note-0002){ref-type="fn"}   5.94 ± 1.61[\*](#jdi12170-note-0002){ref-type="fn"}
  Total cholesterol (mmol/L)        5.66 ± 1.01     5.79 ± 0.96                                           5.77 ± 0.96                                           5.92 ± 0.88[\*](#jdi12170-note-0002){ref-type="fn"}
  Triglycerides (mmol/L)            2.68 ± 2.13     1.66 ± 0.80[\*](#jdi12170-note-0002){ref-type="fn"}   1.40 ± 0.75[\*](#jdi12170-note-0002){ref-type="fn"}   1.11 ± 0.51[\*](#jdi12170-note-0002){ref-type="fn"}
  Non‐HDL cholesterol (mmol/L)      4.68 ± 1.01     4.53 ± 0.95[\*](#jdi12170-note-0002){ref-type="fn"}   4.26 ± 0.96[\*](#jdi12170-note-0002){ref-type="fn"}   4.04 ± 0.89[\*](#jdi12170-note-0002){ref-type="fn"}

Data are expressed as mean ± standard deviation. \**P* \< 0.05 compared with the first quartile, adjusted for age, sex and category of oral glucose tolerance test. BMI, body mass index; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; HDLC, high‐density lipoprotein cholesterol; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; SBP, systolic blood pressure.

John Wiley & Sons, Ltd

###### Clinical characteristics at baseline among native Japanese participants

                                    HDLC                                                                                                                        
  --------------------------------- --------------- ----------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  *n* (NGT/IGT)                     310 (170/140)   257 (105/152)                                         249 (88/161)                                          256 (75/181)
  Developed type 2 diabetes (*n*)   69              35                                                    38                                                    33
  Age (years)                       62.3 ± 7.6      61.6 ± 7.1                                            61.9 ± 6.6                                            61.5 ± 6.9
  SBP (mmHg)                        132 ± 18        131 ± 17                                              132 ± 18                                              129 ± 19
  DBP (mmHg)                        79 ± 10         76 ± 10[\*](#jdi12170-note-0003){ref-type="fn"}       77 ± 10                                               76 ± 11[\*](#jdi12170-note-0003){ref-type="fn"}
  BMI (kg/m^2^)                     24.0 ± 2.8      23.5 ± 2.9                                            22.5 ± 2.8[\*](#jdi12170-note-0003){ref-type="fn"}    21.8 ± 2.9[\*](#jdi12170-note-0003){ref-type="fn"}
  Fasting glucose (mmol/L)          5.49 ± 0.50     5.49 ± 0.50                                           5.38 ± 0.52[\*](#jdi12170-note-0003){ref-type="fn"}   5.33 ± 0.55[\*](#jdi12170-note-0003){ref-type="fn"}
  2‐h glucose (mmol/L)              7.33 ± 1.61     7.16 ± 1.66                                           6.94 ± 1.78[\*](#jdi12170-note-0003){ref-type="fn"}   6.60 ± 1.66[\*](#jdi12170-note-0003){ref-type="fn"}
  Total cholesterol (mmol/L)        5.48 ± 0.93     5.77 ± 0.93[\*](#jdi12170-note-0003){ref-type="fn"}   5.77 ± 0.96[\*](#jdi12170-note-0003){ref-type="fn"}   5.97 ± 0.83[\*](#jdi12170-note-0003){ref-type="fn"}
  Triglycerides (mmol/L)            1.77 ± 0.89     1.43 ± 1.03[\*](#jdi12170-note-0003){ref-type="fn"}   1.21 ± 0.73[\*](#jdi12170-note-0003){ref-type="fn"}   0.99 ± 0.43[\*](#jdi12170-note-0003){ref-type="fn"}
  Non‐HDL cholesterol (mmol/L)      4.34 ± 0.92     4.29 ± 0.94                                           4.02 ± 0.97[\*](#jdi12170-note-0003){ref-type="fn"}   3.75 ± 0.84[\*](#jdi12170-note-0003){ref-type="fn"}

Data are expressed as mean ± standard deviation. \**P* \< 0.05 compared with the first quartile, adjusted for age, sex and category of oral glucose tolerance test. BMI, body mass index; DBP, diastolic blood pressure; HDL, high‐density lipoprotein; HDLC, high‐density lipoprotein cholesterol; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; SBP, systolic blood pressure.

John Wiley & Sons, Ltd

Hazard ratios per unit of serum HDLC level (mmol/L) after adjustment for age and sex were 0.292 (95% confidence interval \[CI\] 0.186--0.458, *P *\< 0.0001) among Japanese--Americans, and 0.551 (95% CI 0.375--0.88, *P *= 0.0023) among native Japanese. Corresponding hazard ratios after adjustment for age, sex, category of OGTT, and BMI were 0.981 (95% CI 0.970--0.993, *P *= 0.0018) and 0.991 (95% CI 0.980--1.002, *P *= 0.112), respectively. In the Cox proportional hazards model including quartiles of HDLC level, hazard ratios for development of diabetes adjusted for age and sex by increasing quartile of HDLC level were 1.0, 0.587 (95% CI 0.404--0.851), 0.468 (95% CI 0.307--0.714), and 0.358 (95% CI 0.229--0.558) among Japanese--Americans, respectively (*P *\< 0.0001 for trend), and after adjustment for age, sex, category of OGTT, and BMI hazard ratios were 1.0, 0.821 (95% CI 0.560--1.204), 0.722 (95% CI 0.468--1.115), and 0.565 (95% CI 0.355--0.898), respectively (*P *= 0.012 for trend) (Figure [1](#jdi12170-fig-0001){ref-type="fig"}a). Hazard ratios for development of diabetes adjusted for age and sex by increasing quartile of HDLC level were 1.0, 0.558 (95% CI 0.371--0.840), 0.620 (95% CI 0.415--0.926), and 0.533 (95% CI 0.350--0.814) among native Japanese, respectively (*P *= 0.0038 for trend), and after adjustment for age, sex, category of OGTT, and BMI hazard ratios were 1.0, 0.601 (95% CI 0.401--0.904), 0.799 (95% CI 0.531--1.204), and 0.818 (95% CI 0.527--1.271), respectively (*P *= 0.936 for trend; Figure [1](#jdi12170-fig-0001){ref-type="fig"}b).

![(a) Adjusted hazard ratios of type 2 diabetes among Japanese--Americans according to baseline serum HDLC concentrations from a Cox proportional hazards model. Bars represent 95% confidence intervals. Statistical significance of trend analysis: *P *\< 0.0001 adjusted for age and sex (left side), *P *= 0.012 adjusted for age, sex, category of oral glucose tolerance test (OGTT; right side) and body mass index (BMI; right side). (b) Corresponding hazard ratios among native Japanese participants. Bars represent 95% confidence intervals. Statistical significance of trend analysis: *P *= 0.038 adjusted for age and sex (left side), *P *= 0.936 adjusted for age, sex, category of OGTT and BMI (right side). \**P *\< 0.05 compared with the first quartile.](jdi-5-501-g1){#jdi12170-fig-0001}

Discussion {#jdi12170-sec-0010}
==========

The main finding of the present study is that a relationship exists between serum HDLC level and the development of type 2 diabetes both in Japanese--Americans and native Japanese. In addition, low serum HDLC level is strongly indicative of development of diabetes in Japanese--Americans compared with native Japanese. This result suggests that low HDLC level should be recognized as a risk factor for diabetes, especially among highly Westernized subjects.

In the present study, we assumed that serum HDLC level serves as an indicator of HDL. In other words, a high HDLC level indicates a high level of HDL anti‐atherosclerosis and antidiabetes properties, such as anti‐inflammatory and anti‐oxidative effects of paraoxonase and apolipoprotein A‐I (apoA‐I) activity[17](#jdi12170-bib-0017){ref-type="ref"}. Accordingly, low HDL level was associated with development of type 2 diabetes after simple adjustment for age and sex in both Japanese--Americans and native Japanese. In addition, recent studies have shown that HDL level could be linked to the pathogenesis of type 2 diabetes because of the capacity of HDL to enhance pancreatic β‐cell function and glucose uptake by skeletal muscle through adenosine monophosphate‐activated protein kinase[18](#jdi12170-bib-0018 jdi12170-bib-0019){ref-type="ref"}. HDL also protects against stress‐induced β‐cell apoptosis and islet inflammation[20](#jdi12170-bib-0020 jdi12170-bib-0021){ref-type="ref"}. Consequently, individuals with low HDLC level might have insufficient insulin secretion and inadequate glucose uptake in skeletal muscle. In contrast, higher HDLC level, as well as higher HDLC/apoA‐I and HDLC/apoA‐II ratios, are reported to lower the risk of future development of type 2 diabetes[22](#jdi12170-bib-0022){ref-type="ref"}. In mice, a global deletion of apoA‐I resulted in impaired glucose tolerance[23](#jdi12170-bib-0023){ref-type="ref"}, whereas apoA‐I overexpression increased insulin sensitivity[24](#jdi12170-bib-0024){ref-type="ref"}. ApoA‐I stimulates the adenosine monophosphate‐activated protein kinase pathway in myocytes *in vitro*[23](#jdi12170-bib-0023){ref-type="ref"}. Therefore, HDL and apoA‐I could increase insulin sensitivity and decrease insulin resistance. This raises the possibility that differences in apoA‐I concentration might be related to the varied HDL effects on type 2 diabetes between Japanese--Americans and native Japanese.

We showed that, although trend analysis of the effect of HDLC on the development of type 2 diabetes after adjustment for age and sex was statistically significant both in Japanese--Americans and native Japanese, trend analysis after further adjustment for category of OGTT and BMI was statistically significant only in Japanese--Americans. With respect to category of HDLC level in the present study, the first and second quartiles among Japanese--Americans corresponded approximately to the first quartile among native Japanese, and the third quartile among Japanese--Americans overlapped almost completely with the second quartile among native Japanese. Therefore, it is possible that the trend in effect of HDLC level on development of type 2 diabetes among Japanese--Americans provides evidence of the same effect in the first and second quartiles among native Japanese. It suggests that, although HDLC level plays a protective role in prevention of type 2 diabetes in Japanese--Americans and native Japanese, it might be rate limiting, especially when HDLC level is very low.

The present study had several limitations. First, although participants did not have diabetes at baseline, medications for other medical conditions might have affected the study\'s findings. However, as far as we could ascertain in our investigations, medication use did not differ among the four quartiles of HDLC participants (data not shown). Second, in only native Japanese participants, we had no data regarding family history of diabetes. Therefore, we were unable to use family history of diabetes as an adjustment factor. Third, HDLC level is generally known to be higher among women than among men, but we analyzed both sexes together. However, the numbers of men and women were almost the same in both populations of Japanese--Americans and native Japanese, and we used sex as an adjustment factor in all analyses, which provides a more powerful analysis than subset analyses separately for each sex as long as the sex adjustment is valid (i.e., there was no interaction between sex and other factors, as such interactions were not included in our models). Fourth, in the present study, fasting glucose and 2‐h glucose were significantly higher in native Japanese than in Japanese--Americans, because the criteria for undergoing OGTT differed between Japanese--Americans and native Japanese. Furthermore, the number of IGT participants was larger among native Japanese than among Japanese--Americans, although the number of developed type 2 diabetes was lower among native Japanese than among Japanese--Americans, which might have affected the results. Finally, the present study was observational. Hence, whether low HDLC is a cause of diabetes development is unclear. Further examination will be required.

In summary, we provide evidence that low HDLC level might be a risk factor for development of type 2 diabetes. This finding has the potential to add a new dimension to understanding the clinical relationship between glucose metabolism and HDLC level. The present study also suggests that HDL could exert a beneficial metabolic effect for prevention not only of cardiovascular disease, but also diabetes, especially in Japanese--American subjects with low HDLC level.
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